US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Psyence Biomedical Ltd

1.76

-0.0500-2.76%

Post-market: 1.770.0100+0.57%19:50 EST

Volume:61.88K

Turnover:110.86K

Market Cap:3.29M

PE:-0.32

High:1.85

Open:1.81

Low:1.76

Close:1.81

52wk High:62.72

52wk Low:1.41

Shares:1.87M

Float Shares:1.86M

Volume Ratio:0.30

T/O Rate:3.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.5651

EPS(LYR):5.24

ROE:-74.29%

ROA:-34.44%

PB:0.28

PE(LYR):0.34

Loading ...

Overview Company News Filings

Psyence BioMed Launches Psilocybin Longevity Research Program

Psyence BioMed Takes Minority Stake in PsyLabs to Boost African Ibogaine Operations

WellsCare Partners with SolnanoMed to Launch IASO and IASO Ultra in Thailand

Psyence BioMed Invests in PsyLabs to Establish Ibogaine Operations in Africa

Psyence Biomed Establishes Ibogaine Operations in Africa Through Strategic Investment in Psylabs

THOMSON REUTERS

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

Benzinga_recent_news

Psyence BioMed Doses Multiple Patients in Phase IIb Psilocybin Trial for Adjustment Disorder

Psyence Biomed Doses Multiple Patients and Expands Clinical Sites in Phase Iib Study for Adjustment Disorder in Palliative Care

THOMSON REUTERS

Analysts Lower Cigna Targets As PBM Segment Guidance Surprises Market

Psyence BioMed Invests $3.5 Million in PsyLabs

Psyence Biomed Strengthens Strategic Partnership With Psylabs Through USD $3,500,000 Follow-on Investment

THOMSON REUTERS

The Pharmacy Stock That's Cheaper Than It Should Be

BRIEF-Psyence Biomedical's chairman, Jody Aufrichtig, assumes role Of CEO

Psyence Biomedical Ltd: Neil Maresky Has Transitioned From His Role as CEO and Director to Serve as Co’s Global Head, Clinical Development

THOMSON REUTERS

Psyence Biomedical Ltd: Co’s Chairman, Jody Aufrichtig, Has Assumed Role of CEO

THOMSON REUTERS

Psyence Biomedical names Jody Aufrichtig as CEO as Neil Maresky transitions to lead clinical development

Masverse and Lembaga Zakat Selangor Pioneer Blockchain-Based Zakat Distribution through e-Wakalah Proof-of-Concept

Psyence Biomedical: Files Prospectus Relates to Potential Offer, Resale, From Time to Time 50 Mln Common Shares by White Lion Capital, Llc

THOMSON REUTERS

Psyence Group Inc. Signs Letter of Intent to Acquire GoldCoast Resource Corp., Advances $250,000 Secured Loan for Exploration Preparation

EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PBM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBM\",,,,,undefined,":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":1.76,"timestamp":1764968400000,"preClose":1.81,"halted":0,"volume":61884,"hourTrading":{"tag":"盘后","latestPrice":1.77,"preClose":1.76,"latestTime":"19:50 EST","volume":6186,"amount":10920.9938,"timestamp":1764982229113},"delay":0,"floatShares":1859800,"shares":1867200,"eps":-5.565065,"marketStatus":"Closed","change":-0.05,"latestTime":"12-05 16:00:00 EST","open":1.81,"high":1.85,"low":1.76,"amount":110857.3638624,"amplitude":0.049724,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.565065,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.81,"preHourTrading":{"tag":"盘前","latestPrice":1.81,"preClose":1.81,"latestTime":"09:29 EST","volume":5374,"amount":9560.0418316,"timestamp":1764944999050},"postHourTrading":{"tag":"盘后","latestPrice":1.77,"preClose":1.76,"latestTime":"19:50 EST","volume":6186,"amount":10920.9938,"timestamp":1764982229113},"volumeRatio":0.297389},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBM\",,,,,undefined,":{"symbol":"PBM","floatShares":1859800,"roa":"-34.44%","roe":"-74.29%","lyrEps":5.241267,"volumeRatio":0.297389,"shares":1867200,"dividePrice":0,"high":1.85,"amplitude":0.049724,"preClose":1.81,"low":1.76,"week52Low":1.41,"pbRate":"0.28","week52High":62.7239,"institutionHeld":0.0125,"latestPrice":1.76,"eps":-5.565065,"divideRate":0,"volume":61884,"delay":0,"ttmEps":-5.565065,"open":1.81,"prevYearClose":16.8167,"prevWeekClose":1.535,"prevMonthClose":1.535,"prevQuarterClose":3.2,"fiveDayClose":1.535,"twentyDayClose":2.513,"sixtyDayClose":3.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-05","symbol":"PBM","defaultRemindTime":1746451800000,"type":"split","dateTimestamp":1746417600000,"forFactor":797,"toFactor":100,"ratio":7.97},{"market":"US","date":"2024-11-26","symbol":"PBM","defaultRemindTime":1732631400000,"type":"split","dateTimestamp":1732597200000,"forFactor":75,"toFactor":1,"ratio":75}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PBM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PBM","date":"2025-12-04","current":-0.323446,"percent":0.26087,"low":-8.987173,"twenty":-1.92814,"median":-0.062237,"eighty":1.579517,"high":43.62106,"avg":0.692829,"sd":6.225812,"marketCap":3332250},"quantilePoints":[{"date":"2024-02-09","current":-4.032357,"twenty":-6.238869,"median":-6.072412,"eighty":-4.789887,"marketCap":12687649},{"date":"2024-02-16","current":-2.839339,"twenty":-6.098548,"median":-3.798256,"eighty":-3.119893,"marketCap":8908805},{"date":"2024-02-23","current":-2.317077,"twenty":-5.416526,"median":-3.308726,"eighty":-2.830575,"marketCap":7275145},{"date":"2024-03-01","current":-2.358335,"twenty":-4.411122,"median":-2.857169,"eighty":-2.443954,"marketCap":7364862},{"date":"2024-03-08","current":-5.40272,"twenty":-4.595223,"median":-2.890292,"eighty":-2.448252,"marketCap":17006136},{"date":"2024-03-15","current":-6.789855,"twenty":-5.670597,"median":-3.448439,"eighty":-2.49853,"marketCap":21291147},{"date":"2024-03-22","current":-4.959176,"twenty":-5.522615,"median":-3.851628,"eighty":-2.531651,"marketCap":15533164},{"date":"2024-03-28","current":-5.045126,"twenty":-5.473209,"median":-4.390178,"eighty":-2.58397,"marketCap":15800977},{"date":"2024-04-05","current":-4.43423,"twenty":-5.384879,"median":-4.562142,"eighty":-2.723572,"marketCap":13926285},{"date":"2024-04-12","current":-3.616183,"twenty":-5.308825,"median":-4.386712,"eighty":-2.826193,"marketCap":11169148},{"date":"2024-04-19","current":-2.969424,"twenty":-5.158983,"median":-4.227564,"eighty":-2.846471,"marketCap":9153854},{"date":"2024-04-26","current":-3.634228,"twenty":-5.044947,"median":-3.989124,"eighty":-2.883667,"marketCap":11244136},{"date":"2024-05-03","current":-5.498334,"twenty":-5.135216,"median":-4.022166,"eighty":-2.931227,"marketCap":17006136},{"date":"2024-05-10","current":-4.755664,"twenty":-5.044947,"median":-4.198236,"eighty":-2.950931,"marketCap":14729724},{"date":"2024-05-17","current":-3.914422,"twenty":-5.029183,"median":-4.161003,"eighty":-2.965515,"marketCap":12185499},{"date":"2024-05-24","current":-3.576034,"twenty":-4.995271,"median":-3.989124,"eighty":-2.992841,"marketCap":11063362},{"date":"2024-05-31","current":-2.410174,"twenty":-4.97525,"median":-3.912167,"eighty":-2.927321,"marketCap":10042674},{"date":"2024-06-07","current":-2.153089,"twenty":-4.945403,"median":-3.739796,"eighty":-2.692286,"marketCap":8971456},{"date":"2024-06-14","current":-1.939708,"twenty":-4.890182,"median":-3.700097,"eighty":-2.466859,"marketCap":8082344},{"date":"2024-06-21","current":-1.253291,"twenty":-4.889663,"median":-3.668675,"eighty":-2.422386,"marketCap":5222190},{"date":"2024-06-28","current":-0.96407,"twenty":-4.844987,"median":-3.634228,"eighty":-2.361971,"marketCap":4017069},{"date":"2024-07-05","current":-0.935148,"twenty":-4.815866,"median":-3.576034,"eighty":-2.32332,"marketCap":3896557},{"date":"2024-07-12","current":-0.998455,"twenty":-4.766248,"median":-3.491099,"eighty":-2.088818,"marketCap":4160345},{"date":"2024-07-19","current":-1.323989,"twenty":-4.726555,"median":-3.448439,"eighty":-1.937394,"marketCap":5516775},{"date":"2024-07-26","current":-1.867403,"twenty":-4.683035,"median":-3.197485,"eighty":-1.910851,"marketCap":7781064},{"date":"2024-08-02","current":-0.143956,"twenty":-4.658595,"median":-2.969424,"eighty":-1.31949,"marketCap":7364628},{"date":"2024-08-09","current":-0.138564,"twenty":-4.597134,"median":-2.93318,"eighty":-1.252648,"marketCap":7088789},{"date":"2024-08-16","current":-0.175224,"twenty":-4.56626,"median":-2.839339,"eighty":-1.14223,"marketCap":8964295},{"date":"2024-08-23","current":-0.164846,"twenty":-4.484876,"median":-2.620747,"eighty":-1.025128,"marketCap":8433350},{"date":"2024-08-30","current":-0.133743,"twenty":-4.446042,"median":-2.530201,"eighty":-0.96664,"marketCap":6842183},{"date":"2024-09-06","current":-0.062172,"twenty":-4.437003,"median":-2.444094,"eighty":-0.946331,"marketCap":3180663},{"date":"2024-09-13","current":-0.050913,"twenty":-4.377208,"median":-2.41628,"eighty":-0.171823,"marketCap":2604637},{"date":"2024-09-20","current":-0.039131,"twenty":-4.329259,"median":-2.362614,"eighty":-0.163756,"marketCap":2001897},{"date":"2024-09-27","current":-0.035312,"twenty":-4.305444,"median":-2.355493,"eighty":-0.148457,"marketCap":1806550},{"date":"2024-10-04","current":-0.032669,"twenty":-4.254131,"median":-2.317077,"eighty":-0.14305,"marketCap":1671309},{"date":"2024-10-11","current":-0.031494,"twenty":-4.19237,"median":-2.120953,"eighty":-0.135288,"marketCap":1611202},{"date":"2024-10-18","current":-0.035247,"twenty":-4.164165,"median":-2.088818,"eighty":-0.127633,"marketCap":1803210},{"date":"2024-10-25","current":-0.031592,"twenty":-4.083815,"median":-1.933924,"eighty":-0.075611,"marketCap":1616211},{"date":"2024-11-01","current":-0.02265,"twenty":-4.026242,"median":-1.927818,"eighty":-0.057485,"marketCap":1158729},{"date":"2024-11-08","current":-0.024869,"twenty":-3.982516,"median":-1.638758,"eighty":-0.044294,"marketCap":1272265},{"date":"2024-11-15","current":-0.049784,"twenty":-3.931086,"median":-1.323989,"eighty":-0.044294,"marketCap":2546883},{"date":"2024-11-22","current":-0.042798,"twenty":-3.911717,"median":-1.256183,"eighty":-0.044338,"marketCap":2189514},{"date":"2024-11-29","current":-0.045389,"twenty":-3.854339,"median":-1.251684,"eighty":-0.044435,"marketCap":2322054},{"date":"2024-12-06","current":-0.046144,"twenty":-3.758505,"median":-1.181949,"eighty":-0.045374,"marketCap":2360678},{"date":"2024-12-13","current":-0.036019,"twenty":-3.736446,"median":-1.098558,"eighty":-0.042081,"marketCap":1842723},{"date":"2024-12-20","current":-0.213027,"twenty":-3.720507,"median":-1.025128,"eighty":-0.041056,"marketCap":10898254},{"date":"2024-12-27","current":-0.195572,"twenty":-3.702521,"median":-0.998455,"eighty":-0.041494,"marketCap":10005291},{"date":"2025-01-03","current":-0.174804,"twenty":-3.696057,"median":-0.967283,"eighty":-0.041676,"marketCap":8942782},{"date":"2025-01-10","current":-0.147112,"twenty":-3.67593,"median":-0.957643,"eighty":-0.042486,"marketCap":7526104},{"date":"2025-01-17","current":-0.1549,"twenty":-3.667341,"median":-0.574087,"eighty":-0.042776,"marketCap":7924545},{"date":"2025-01-24","current":-0.172934,"twenty":-3.665023,"median":-0.208553,"eighty":-0.043408,"marketCap":8057358},{"date":"2025-01-31","current":-0.14918,"twenty":-3.646165,"median":-0.184323,"eighty":-0.044744,"marketCap":6950578},{"date":"2025-02-07","current":-0.129701,"twenty":-3.623401,"median":-0.178377,"eighty":-0.045379,"marketCap":6043019},{"date":"2025-02-14","current":-0.132551,"twenty":-3.592094,"median":-0.174804,"eighty":-0.045783,"marketCap":6175832},{"date":"2025-02-21","current":-0.123525,"twenty":-3.571282,"median":-0.172934,"eighty":-0.046085,"marketCap":5755256},{"date":"2025-02-28","current":-0.117823,"twenty":-3.543472,"median":-0.170272,"eighty":-0.046183,"marketCap":5489629},{"date":"2025-03-07","current":-0.087417,"twenty":-3.495369,"median":-0.16615,"eighty":-0.046596,"marketCap":4072950},{"date":"2025-03-14","current":-0.074485,"twenty":-3.463351,"median":-0.163664,"eighty":-0.047435,"marketCap":3470419},{"date":"2025-03-21","current":-0.059349,"twenty":-3.451625,"median":-0.159632,"eighty":-0.048363,"marketCap":2765179},{"date":"2025-03-28","current":-0.05971,"twenty":-3.386977,"median":-0.158361,"eighty":-0.049116,"marketCap":2782002},{"date":"2025-04-04","current":-0.04489,"twenty":-3.267253,"median":-0.1549,"eighty":-0.049116,"marketCap":2091532},{"date":"2025-04-11","current":-0.043618,"twenty":-3.203179,"median":-0.154152,"eighty":-0.046323,"marketCap":2032227},{"date":"2025-04-17","current":-0.042568,"twenty":-3.140804,"median":-0.151236,"eighty":-0.046065,"marketCap":1983334},{"date":"2025-04-25","current":-0.053422,"twenty":-3.016258,"median":-0.148843,"eighty":-0.045369,"marketCap":2489014},{"date":"2025-05-02","current":-0.04217,"twenty":-2.968121,"median":-0.146958,"eighty":-0.044944,"marketCap":1964773},{"date":"2025-05-09","current":-0.047195,"twenty":-2.958916,"median":-0.143956,"eighty":-0.045202,"marketCap":2198901},{"date":"2025-05-16","current":-0.065096,"twenty":-2.939039,"median":-0.143033,"eighty":-0.045369,"marketCap":3032967},{"date":"2025-05-23","current":-0.055332,"twenty":-2.910166,"median":-0.139192,"eighty":-0.045482,"marketCap":2578022},{"date":"2025-05-30","current":-0.065345,"twenty":-2.857169,"median":-0.138564,"eighty":-0.045852,"marketCap":3044574},{"date":"2025-06-06","current":-0.063844,"twenty":-2.839339,"median":-0.135018,"eighty":-0.046045,"marketCap":2974641},{"date":"2025-06-13","current":-0.058023,"twenty":-2.817429,"median":-0.132806,"eighty":-0.046068,"marketCap":2703424},{"date":"2025-06-20","current":-0.061591,"twenty":-2.692286,"median":-0.131126,"eighty":-0.046129,"marketCap":2869653},{"date":"2025-06-27","current":26.979573,"twenty":-2.596595,"median":-0.130176,"eighty":-0.046129,"marketCap":27297662},{"date":"2025-07-03","current":27.487604,"twenty":-2.551768,"median":-0.129464,"eighty":-0.045667,"marketCap":27811683},{"date":"2025-07-11","current":26.19376,"twenty":-2.531167,"median":-0.127325,"eighty":-0.04489,"marketCap":26502584},{"date":"2025-07-18","current":27.61963,"twenty":-2.482695,"median":-0.125116,"eighty":-0.043883,"marketCap":27945265},{"date":"2025-07-25","current":5.7589,"twenty":-2.446866,"median":-0.121624,"eighty":-0.042776,"marketCap":5826797},{"date":"2025-08-01","current":2.899625,"twenty":-2.443883,"median":-0.117823,"eighty":-0.042564,"marketCap":2933812},{"date":"2025-08-08","current":2.409629,"twenty":-2.430929,"median":-0.116873,"eighty":-0.041187,"marketCap":2438039},{"date":"2025-08-15","current":1.931163,"twenty":-2.415059,"median":-0.115922,"eighty":-0.040303,"marketCap":1953931},{"date":"2025-08-22","current":1.844692,"twenty":-2.395713,"median":-0.095437,"eighty":-0.03915,"marketCap":1866441},{"date":"2025-08-29","current":1.712105,"twenty":-2.371998,"median":-0.086044,"eighty":-0.036019,"marketCap":1732291},{"date":"2025-09-05","current":1.487283,"twenty":-2.362357,"median":-0.084153,"eighty":-0.035684,"marketCap":1504818},{"date":"2025-09-12","current":1.867751,"twenty":-2.360517,"median":-0.075977,"eighty":-0.035051,"marketCap":1889772},{"date":"2025-09-19","current":3.055271,"twenty":-2.356062,"median":-0.074774,"eighty":-0.033798,"marketCap":3091293},{"date":"2025-09-26","current":1.769752,"twenty":-2.341544,"median":-0.069101,"eighty":-0.031722,"marketCap":1790617},{"date":"2025-10-03","current":1.896574,"twenty":-2.321759,"median":-0.068517,"eighty":-0.030678,"marketCap":1918935},{"date":"2025-10-10","current":2.132926,"twenty":-2.285546,"median":-0.066599,"eighty":-0.029539,"marketCap":2158073},{"date":"2025-10-17","current":1.988809,"twenty":-2.204185,"median":-0.065502,"eighty":-0.025065,"marketCap":2012257},{"date":"2025-10-24","current":1.922516,"twenty":-2.127381,"median":-0.065096,"eighty":-0.022271,"marketCap":1945182},{"date":"2025-10-31","current":1.80434,"twenty":-2.088818,"median":-0.063691,"eighty":1.436554,"marketCap":1825613},{"date":"2025-11-07","current":1.448659,"twenty":-2.088818,"median":-0.062888,"eighty":1.555882,"marketCap":1465739},{"date":"2025-11-14","current":1.608341,"twenty":-2.06311,"median":-0.062194,"eighty":1.555882,"marketCap":1627303},{"date":"2025-11-21","current":3.182406,"twenty":-1.990611,"median":-0.061648,"eighty":1.615259,"marketCap":3219927},{"date":"2025-11-28","current":-0.729044,"twenty":-1.937394,"median":-0.062172,"eighty":1.602576,"marketCap":2873598},{"date":"2025-12-04","current":-0.845406,"twenty":-1.92814,"median":-0.062237,"eighty":1.579517,"marketCap":3332250}],"updateTime":1764961322364},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586992420","title":"Psyence BioMed Launches Psilocybin Longevity Research Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2586992420","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586992420?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:11","pubTimestamp":1764072701,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has announced the launch of a pioneering psilocybin longevity research program in collaboration with researchers in South Africa. The initiative aims to investigate the potential impact of psilocybin on biological markers associated with aging, including cellular stress, inflammation, mitochondrial function, and behavioral indicators of healthspan and lifespan. The research, led by Dr. Tanya Calvey, is currently in the project commencement phase, with accelerated progress expected early next year following ethics approval. No scientific results have been presented yet; the study is in its early stages.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL1svZPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2585299129","title":"Psyence BioMed Takes Minority Stake in PsyLabs to Boost African Ibogaine Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2585299129","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585299129?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:18","pubTimestamp":1763763527,"startTime":"0","endTime":"0","summary":"Psyence BioMed, a biopharmaceutical company focused on nature-derived psilocybin and ibogaine therapies, has made a strategic equity investment in PsyLabs. This transaction establishes Psyence BioMed as the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa, the original source of ibogaine. The investment strengthens Psyence BioMed's supply chain and provides shareholders with early access to pipeline products, intellectual property development, and supply channels as global demand for psychedelic active pharmaceutical ingredients  increases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL6HcXWw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2584690998","title":"WellsCare Partners with SolnanoMed to Launch IASO and IASO Ultra in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2584690998","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584690998?lang=en_us&edition=fundamental","pubTime":"2025-11-17 10:00","pubTimestamp":1763344800,"startTime":"0","endTime":"0","summary":"Partnership to Bring Innovative Wearable Cold-Laser Therapy to One of Southeast Asia's Fastest-Growing Healthcare Markets  SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ -- WellsCare Inc., a leading South Korean med-tech innovator in wearable cold-laser therapy, today announced that it has signed a supply agreement with SolnanoMed Co., Ltd., one of Thailand's most respected medical device distributors. The agreement follows WellsCare's recent FDA Thai approval for its flagship product, IASO Coldlaser — advanced photobiomodulation  therapy device designed for effective, drug-free pain management.IASO products come with convenient wearable bands and hydrocolloid adhesive patches so that you can wear the device hands-free, anywhere you experience pain.Through this partnership, SolnanoMed will serve as WellsCare's exclusive distributor in Thailand, covering hospitals, clinics, and retail channels nationwide. Together, the two companies aim to make hospital-grade pain-relief technology acce","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2822259/WellsCare__co_ltd_Photos_attached_to_press_releases_20251111.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2822259/WellsCare__co_ltd_Photos_attached_to_press_releases_20251111.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/wellscare-partners-with-solnanomed-to-launch-iaso-and-iaso-ultra-in-thailand-302614265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2582163373","title":"Psyence BioMed Invests in PsyLabs to Establish Ibogaine Operations in Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=2582163373","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582163373?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948835,"startTime":"0","endTime":"0","summary":"Psyence BioMed, a biopharmaceutical company focused on nature-derived psilocybin and ibogaine therapies, has made a strategic equity investment in PsyLabs. Through this investment, Psyence BioMed becomes the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa, the original source of ibogaine. The partnership strengthens Psyence BioMed's supply chain and positions the company to deliver sustainable, ethical, and science-driven psychedelic therapies to a global market. Shareholders are expected to benefit from early access to pipeline products, intellectual property development, and secure supply channels as demand for psychedelic APIs grows worldwide.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7t8Vp2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD","PBM","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4139"],"gpt_icon":0},{"id":"2582373936","title":"Psyence Biomed Establishes Ibogaine Operations in Africa Through Strategic Investment in Psylabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373936?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA3DCHXD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2582422375","title":"Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'","url":"https://stock-news.laohu8.com/highlight/detail?id=2582422375","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582422375?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:22","pubTimestamp":1762946520,"startTime":"0","endTime":"0","summary":"Eli Lilly CEO Dave Ricks slams PBM \"rent taking\" for driving $275 insulin price bubble and explains why he's ready to \"disintermediate them.\"","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/12/Prague--Czechia---30--May-2025-Eli-Lilly.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/12/Prague--Czechia---30--May-2025-Eli-Lilly.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48797823/eli-lilly-ceo-slams-pbm-rent-taking-says-they-drove-insulin-list-prices-to-275-we-can-disintermediate-them-easily","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48797823/eli-lilly-ceo-slams-pbm-rent-taking-says-they-drove-insulin-list-prices-to-275-we-can-disintermediate-them-easily","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","IE00BFTCPJ56.SGD","LU0456855351.SGD","IE00B4R5TH58.HKD","LU0256863811.USD","IE00BJLML261.HKD","LU2360106947.USD","LU0385154629.USD","LU2456880835.USD","SGXZ81514606.USD","IE00BKDWB100.SGD","PBM","LU2471134952.CNY","LU2552382132.HKD","LLY","LU2552382058.USD","BK4588","LU0820561818.USD","IE00B1XK9C88.USD","LU2324357040.USD","LU1232071149.USD","LU0320765059.SGD","LU2236285917.USD","LU2265009873.SGD","LU0708995401.HKD","LU2552382215.SGD","BK4599","LU2602419157.SGD","LU0466842654.USD","LU0097036916.USD","LU0786609619.USD","LU1551013342.USD","LU0061475181.USD","LU2237438978.USD","LU0889565916.HKD","LU1988902786.USD","LU0640476718.USD","LU0353189763.USD","LU2471134879.HKD","LU0316494557.USD","LU1064131342.USD","LU1280957306.USD","LU0882574055.USD","LU2112291526.USD","LU0094547139.USD","LU0689472784.USD","LU2471134523.USD","LU0432979614.USD","LU2237443465.HKD","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"2581106299","title":"Psyence BioMed Doses Multiple Patients in Phase IIb Psilocybin Trial for Adjustment Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2581106299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581106299?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430436,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has announced a significant milestone in its ongoing Phase IIb clinical trial evaluating nature-derived psilocybin, in combination with psychotherapy, as a potential treatment for Adjustment Disorder in palliative care. Multiple patients have now been successfully dosed across two active clinical sites-the Empax Center in Perth and the Mind Medicine Australia Clinic in Melbourne. The company has also activated a third site, Paratus Clinical Research in Melbourne, to accelerate enrollment and data collection. The trial is designed to meet rigorous regulatory standards, with a larger sample size, randomized multi-site structure, and aims to generate high-quality data to support future approvals. Topline results from the study are anticipated by the end of 2026. No results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL2009By:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","BK4585","IE00BKPKM429.USD","BK4112","PBM","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0},{"id":"2581642020","title":"Psyence Biomed Doses Multiple Patients and Expands Clinical Sites in Phase Iib Study for Adjustment Disorder in Palliative Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2581642020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581642020?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430412,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA27T9GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2581683507","title":"Analysts Lower Cigna Targets As PBM Segment Guidance Surprises Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2581683507","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581683507?lang=en_us&edition=fundamental","pubTime":"2025-11-05 02:55","pubTimestamp":1762282547,"startTime":"0","endTime":"0","summary":"Cigna expects 2026–2027 margin pressure from its new rebate-free PBM model as major clients renew at lower margins, prompting analyst target cuts.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48632374/analysts-lower-cigna-targets-as-pbm-segment-guidance-surprises-market","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048573561.USD","LU0477156953.USD","LU2237443382.USD","LU0742534661.SGD","LU2471134879.HKD","IE00B19Z3581.USD","LU2237443622.USD","IE0004091025.USD","IE00B19Z3B42.SGD","LU0980610538.SGD","BK4533","BK4550","LU1868836914.USD","LU2471134523.USD","BK4139","BK4504","BK4516","LU0061475181.USD","LU0345770308.USD","LU0106831901.USD","LU2265009873.SGD","LU2237443549.SGD","LU0251142724.SGD","LU1894683348.USD","LU1699723380.USD","LU1868837136.USD","LU1201861165.SGD","IE0002270589.USD","CI","LU1201861249.SGD","IE00BFXG1179.USD","BK4127","LU1791807156.HKD","LU2237443465.HKD","LU2362541513.USD","LU0251131958.USD","BK4154","LU2237438978.USD","LU2362541273.HKD","LU2237443895.HKD","IE00BSNM7G36.USD","LU1868836757.USD","LU2471134952.CNY","BK4585","PBM","LU0648000940.SGD","LU1868836591.USD","LU2237443978.SGD","CNC","LU0130102774.USD"],"gpt_icon":0},{"id":"2580297559","title":"Psyence BioMed Invests $3.5 Million in PsyLabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2580297559","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580297559?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:00","pubTimestamp":1762171228,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has announced a USD $3,500,000 follow-on equity investment in PsyLabs, a leading producer of purified psychedelic active pharmaceutical ingredients. This investment, made on August 15th, 2025, strengthens Psyence BioMed's strategic partnership with PsyLabs and secures access to high-quality, GMP-grade psychedelic compounds for its clinical research programs. The move follows a previous USD $500,000 investment in PsyLabs in April 2025, further solidifying PsyLabs' role as a primary supplier for Psyence BioMed's clinical pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is sol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL6TLvj1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","PBM","NDAQ","LU2210149790.SGD","BK4585","BK4112","BK4139"],"gpt_icon":0},{"id":"2580800297","title":"Psyence Biomed Strengthens Strategic Partnership With Psylabs Through USD $3,500,000 Follow-on Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2580800297","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580800297?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:00","pubTimestamp":1762171205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA61782S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2575733298","title":"The Pharmacy Stock That's Cheaper Than It Should Be","url":"https://stock-news.laohu8.com/highlight/detail?id=2575733298","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575733298?lang=en_us&edition=fundamental","pubTime":"2025-10-15 22:00","pubTimestamp":1760536800,"startTime":"0","endTime":"0","summary":"The company has crushed the market this year and still looks like a steal.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F832666%2Fpharmacist-talking-to-patient.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F832666%2Fpharmacist-talking-to-patient.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/15/the-pharmacy-stock-thats-cheaper-than-it-should-be/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/15/the-pharmacy-stock-thats-cheaper-than-it-should-be/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4559","IE00BWXC8680.SGD","LU0494093205.USD","LU0985320562.USD","LU1868836591.USD","LU0672654240.SGD","LU0689472784.USD","LU0820561909.HKD","LU0868494708.USD","IE00BFSS8Q28.SGD","LU0786609619.USD","LU0823434740.USD","LU1363072403.SGD","BK4585","LU0106261372.USD","LU0276348264.USD","LU2764262908.HKD","MA","LU2552382132.HKD","LU2360106780.USD","LU1989772923.USD","LU2213496289.HKD","LU0256863811.USD","LU2077746001.SGD","LU1691799644.USD","LU0077335932.USD","PBM","LU1261432733.SGD","LU1868836914.USD","BK4527","IE00B1XK9C88.USD","LU2896262040.SGD","IE0004445015.USD","LU2168564149.EUR","LU0889565833.HKD","LU1623119135.USD","LU2108987350.USD","BK4588","LU0640476718.USD","IE00BJJMRX11.SGD","LU2461242641.AUD","LU2756315664.SGD","LU1145028129.USD","LU0942090050.USD","LU2054465674.USD","LU0198837287.USD","LU0353189763.USD","LU2756315318.SGD","IE00B7KXQ091.USD","LU1551013425.SGD"],"gpt_icon":0},{"id":"2574197327","title":"BRIEF-Psyence Biomedical's chairman, Jody Aufrichtig, assumes role Of CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2574197327","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574197327?lang=en_us&edition=fundamental","pubTime":"2025-10-10 05:49","pubTimestamp":1760046573,"startTime":"0","endTime":"0","summary":"BRIEF-Psyence Biomedical's chairman, Jody Aufrichtig, assumes role Of CEOOct 9  - Psyence Biomedical Ltd PBM.O:PSYENCE BIOMEDICAL LTD: CO’S CHAIRMAN, JODY AUFRICHTIG, HAS ASSUMED ROLE OF CEOPSYENCE BIOMEDICAL LTD: NEIL MARESKY HAS TRANSITIONED FROM HIS ROLE AS CEO AND DIRECTOR TO SERVE AS CO’S GLOBAL HEAD, CLINICAL DEVELOPMENTSource text: [ID:n0001213900-25-097819]Further company coverage: PBM.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VQ1AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2574527191","title":"Psyence Biomedical Ltd: Neil Maresky Has Transitioned From His Role as CEO and Director to Serve as Co’s Global Head, Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2574527191","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574527191?lang=en_us&edition=fundamental","pubTime":"2025-10-10 04:19","pubTimestamp":1760041191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VQ1AC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2574191581","title":"Psyence Biomedical Ltd: Co’s Chairman, Jody Aufrichtig, Has Assumed Role of CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2574191581","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574191581?lang=en_us&edition=fundamental","pubTime":"2025-10-10 04:19","pubTimestamp":1760041191,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VQ1AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2574913991","title":"Psyence Biomedical names Jody Aufrichtig as CEO as Neil Maresky transitions to lead clinical development","url":"https://stock-news.laohu8.com/highlight/detail?id=2574913991","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574913991?lang=en_us&edition=fundamental","pubTime":"2025-10-10 04:17","pubTimestamp":1760041071,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has announced that Dr. Neil Maresky has stepped down as Chief Executive Officer and Director to become the company's Global Head of Clinical Development. Jody Aufrichtig, the company's Chairman, has taken on the role of Chief Executive Officer and will oversee corporate operations. The company will fill the resulting Board vacancy at a later date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL1C27Jc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2574900474","title":"Masverse and Lembaga Zakat Selangor Pioneer Blockchain-Based Zakat Distribution through e-Wakalah Proof-of-Concept","url":"https://stock-news.laohu8.com/highlight/detail?id=2574900474","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574900474?lang=en_us&edition=fundamental","pubTime":"2025-10-09 09:46","pubTimestamp":1759974360,"startTime":"0","endTime":"0","summary":"KUALA LUMPUR, Malaysia, Oct. 9, 2025 /PRNewswire/ -- In a landmark collaboration that bridges Islamic finance and emerging technology, Masverse Sdn. Bhd., in cooperation with Lembaga Zakat Selangor  and under the facilitation of Malaysia Digital Economy Corporation , has completed the e-Wakalah Proof-of-Concept . This blockchain-powered platform redefines transparency, efficiency, and accountability in Zakat fund distribution.Representatives from Lembaga Zakat Selangor , Malaysia Digital Economy Corporation , and Masverse Sdn. Bhd. during the e-Wakalah Blockchain Proof-of-Concept official kickoff session, marking a key milestone in advancing transparent and accountable Zakat fund distribution through blockchain innovation.The initiative, officially commissioned through a Letter of Engagement dated 7 May 2024, followed a rigorous selection process where Masverse was shortlisted from several technology companies that submitted proposals to participate in this pioneering effort. All the f","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2792177/IMG_5575_copy.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2792177/IMG_5575_copy.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/masverse-and-lembaga-zakat-selangor-pioneer-blockchain-based-zakat-distribution-through-e-wakalah-proof-of-concept-302579144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM","PACI.U"],"gpt_icon":0},{"id":"2573986481","title":"Psyence Biomedical: Files Prospectus Relates to Potential Offer, Resale, From Time to Time 50 Mln Common Shares by White Lion Capital, Llc","url":"https://stock-news.laohu8.com/highlight/detail?id=2573986481","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573986481?lang=en_us&edition=fundamental","pubTime":"2025-10-07 05:35","pubTimestamp":1759786507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2573622752","title":"Psyence Group Inc. Signs Letter of Intent to Acquire GoldCoast Resource Corp., Advances $250,000 Secured Loan for Exploration Preparation","url":"https://stock-news.laohu8.com/highlight/detail?id=2573622752","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573622752?lang=en_us&edition=fundamental","pubTime":"2025-10-06 15:35","pubTimestamp":1759736103,"startTime":"0","endTime":"0","summary":"Psyence Group Inc. Signs Letter of Intent to Acquire GoldCoast Resource Corp., Advances $250,000 Secured Loan for Exploration Preparation. Psyence Group Inc. has entered into a letter of intent to acquire all issued and outstanding securities of GoldCoast Resource Corp., a company focused on environmentally responsible shallow-water mineral exploration off the south coast of Ghana. As part of the agreement, Psyence will advance a secured loan of US$250,000 to GoldCoast to support the preparation of an exploration license application and a NI 43-101 Qualified Persons report. Trading in Psyence's common shares will remain halted until the transaction is reviewed and all conditions for resumption are met. There is no guarantee the acquisition will be completed as proposed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL63cGFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2572531055","title":"EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2572531055","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572531055?lang=en_us&edition=fundamental","pubTime":"2025-10-01 20:46","pubTimestamp":1759322760,"startTime":"0","endTime":"0","summary":"Scienture Holdings, Inc. announced GPO agreements for its new drug, Arbli, providing access to over 2,500 healthcare institutions and plans to expand further.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/01/Pulmonary-Hypertension-Medicine-Doctor-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/01/Pulmonary-Hypertension-Medicine-Doctor-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/47966068/exclusive-scienture-secures-purchase-agreements-healthcare-institutions","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/47966068/exclusive-scienture-secures-purchase-agreements-healthcare-institutions","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4137","BK4588","HCSG","BK4585","XLV","PBM","BK4139","XBI","SCNX","LABU","BK4167","BK4581"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}